Articles tagged with Cancer Patients
Research on the ATM gene suggests that women carrying one mutated copy are twice as likely to develop breast cancer, with a lifetime risk of one in six compared to one in 11 in the general population. Meanwhile, a new study on ursodeoxycholic acid treatment found a 39% reduction in colorectal adenoma recurrence among patients who recei...
A study by Beth E. Meyerowitz and colleagues found that cancer survivors are twice as likely to experience cognitive deficits, including dementia, compared to their cancer-free twins. The authors suggest that cancer treatments may lower survivors' cognitive reserve, leading to increased risk of long-term cognitive dysfunction.
Researchers at U-M have identified a method that produces viable eggs when thawed, allowing cancer patients to preserve fertility. The vitrification technique enables 98% survival of eggs after thawing, compared to traditional slow-freeze techniques.
Researchers used PET/CT scans to evaluate nearly 2,000 cancer patients and detected unexpected additional malignancies. These newly identified lesions are often of early stage and have a better likelihood of being cured if treated promptly and aggressively.
A clinical trial by Mayo Clinic found that shark cartilage did not demonstrate any efficacy in patients with advanced breast or colorectal cancers. In fact, some quality of life measurements worsened among patients treated with shark cartilage.
Patients who survived at least two years post-transplant showed reduced risk of death each year after the fifth anniversary. Mortality not related to relapse was increased in patients with specific chemotherapy regimens and stem cell sources.
A study found that cetuximab, an Erbitux-based treatment, helped shrink tumors and extend survival in patients with metastatic colorectal cancer who had previously failed treatment. The typical patient survived 6.6 months after treatment.
Panitumumab demonstrated a median survival time of 37.6 weeks and tumor response for 29% of patients with mCRC. The study confirmed safety and efficacy findings previously reported, suggesting panitumumab as an additional treatment option for managing the disease.
A randomized head-to-head study demonstrates Aranesp dosed every two weeks is comparable to Epoetin alfa dosed weekly in terms of transfusion rates and hemoglobin achievement. The study involved over 1,200 patients with chemotherapy-induced anemia and found similar outcomes between the two treatment groups.
A randomized trial found that the ALL-2 regimen of cytarabine with high-dose mitoxantrone improved complete remission rates and survival outcomes for patients with acute lymphocytic leukemia. The regimen demonstrated a significant survival advantage, particularly in patients with the Philadelphia chromosome genetic predisposition.
A Phase 3 study of Aranesp dosed every three weeks achieved a 91% success rate in maintaining target hemoglobin levels, with 72% of patients sustaining the level over 16 weeks. The treatment showed reduced need for red blood cell transfusions and consistent adverse event profile.
A large community-based clinical trial showed a significant reduction in febrile neutropenia and chemotherapy dose reductions among older patients receiving Neulasta. The study found that Neulasta reduced the incidence of serious adverse events, including hospitalizations and pneumonia.
Researchers analyzed tumor DNA from 324 GIST patients and found that those with a KIT exon 11 mutation responded better to Gleevec. The study confirms the need for new drugs for patients whose GIST genotype is less responsive to Gleevec.
Researchers have developed serum proteomic fingerprints for diagnosing gastric cancer, achieving an accuracy rate of 73% in detecting the disease. Additionally, confocal endomicroscopy has been found to be more effective in monitoring ulcerative colitis and detecting precancerous lesions, potentially saving lives.
A phase II trial found that Herceptin can be used safely for bladder cancer with few serious adverse effects related to the drug. The study showed good responses to treatment in patients with HER2-positive bladder cancer, laying the foundation for a future phase III trial.
A new kidney cancer drug has shown a partial response rate of 40% in patients with metastatic renal cell carcinoma, significantly higher than the standard treatment's 15% response rate. The medication, SU11248, was well-tolerated and had significant side effects, but offered improved survival rates for some patients.
Sebastian Nijman's research reveals the molecular mechanism underlying cylindromatosis, a rare genetic condition causing skin tumors. The study also identifies a key protein in Fanconi anaemia, a form of inherited cancer, and finds potential treatment through inhibition of NF-kappa B signalling route.
A clinical trial involving over 730 colorectal cancer patients suggests that keyhole surgery may be the new gold standard for colon cancer treatment, offering rapid recovery rates, less pain, and fewer complications. The study found similar cancer-related survival and quality of life outcomes between keyhole and open surgery groups.
Researchers at Yale University have developed a new blood test for ovarian cancer screening using four biomarkers, showing high sensitivity and specificity. The test predicts cancer in patients whose levels of two or more biomarkers fall within a certain warning area.
Scientists at the University of Utah Health have discovered an enzyme called DGK iota that appears to reduce the incidence of Ras-induced tumors in mice. The researchers found that mice with a deleted DGK iota gene developed fewer tumors, while those with an intact gene and activated Ras exhibited significantly more tumors.
Researchers found that advanced NSCLC patients with high EGFR gene copy number, protein expression, or mutations respond better to gefitinib. High EGFR gene copy number is associated with prolonged survival and disease control.
Metal stents have been shown to be a safe and effective treatment for bile duct obstructions caused by pancreatic cancer. The study found that 90% of patients had open stents after three months and 80% after one year, with minimal complications.
A Northwestern Memorial HealthCare study identified a gene variant TGFBR1*6A associated with a high risk of colorectal cancer. The variant was found to be more prevalent among patients without a mutation in other genes, suggesting its potent contribution to familial cases.
Georgetown University is helping create a national cancer biomedical informatics grid to link research centers in real time, sharing data and results more rapidly. The $20 million grant aims to improve cancer research and treatment through the adoption of common research tools.
Researchers have identified a new tumor suppressor gene, ARLTS1, that increases the risk of cancer in some individuals. The findings suggest that ARLTS1 may play an important role in the development of certain types of cancer, particularly familial cancers.
Researchers have discovered gene portfolios that can define a patient's likelihood of developing cancers, responding to treatment, and fending off malignancies. These 'Death from Cancer Signature' portfolios provide opportunities for early identification and targeted therapies, potentially improving five-year survival rates.
A clinical trial found that systematic aortic and pelvic lymphadenectomy improved progression-free survival, but not overall survival, in patients with advanced ovarian cancer. The procedure did not significantly increase median overall survival duration.
The Lance Armstrong Foundation is supporting a University Hospitals of Cleveland research project exploring the impact of exercise and dietary counseling on obese endometrial cancer patients. Dr. von Gruenigen's study aims to improve quality of life for this high-risk group, which accounts for over 40,000 cases annually in the US.
A new study suggests that mammography is catching breast cancer earlier, but the increasing number of in situ cancers poses a challenge to healthcare professionals. The researchers found a sixfold increase in noncomedo DCIS and a nearly fourfold increase in LCIS among postmenopausal women.
A multicenter trial found that alpha-tocopherol supplementation increased the rate of developing a second primary cancer during treatment but reduced the risk after treatment ended. After 8 years, the proportion of participants free of a second primary cancer was similar in both groups.
A new study found that altering food schedules and light/dark exposure in mice modified the expression of circadian clock genes and genes involved in carcinogenesis and tumor progression. The authors conclude that the altered light/dark or feeding schedules may slow tumor growth in chronic jet-lagged mice.
Randy 'Duke' Cunningham, a prostate cancer survivor, receives funding for cancer research through his committee work. Deidre Downs, Miss America 2005, continues her childhood cancer research efforts through CureSearch and her medical student program.
A meta-analysis of 27 clinical trials found that erythropoietin treatment lowers the likelihood of needing a blood transfusion and improves hematologic response in cancer patients. However, results on overall survival are inconclusive, suggesting erythropoietin should not be used to increase survival outside clinical trials.
Participation in cancer clinical trials improves survival, with significant benefits for Kaposi Sarcoma patients. Young adults with sarcomas face limited treatment options and low clinical trial participation rates, contributing to poor survival rates.
A retrospective study found that African-American women with advanced endometrial cancer have more aggressive tumors, leading to poor survival rates compared to Caucasian patients. The study suggests biologic differences in gene expression may underlie this racial disparity.
Researchers found that a specific viral protein EBNA3C triggers uncontrolled growth of B cells, initiating cancer. The study provides new insights into how Epstein-Barr virus drives cancer and paves the way for developing targeted therapeutics.
A national study of cancer patients who underwent bone marrow transplantation reveals long-term quality of life issues persist for decades. Cancer survivors report lingering sleep, sexual problems, pain, cognitive decline, and poor physical well-being compared to healthy peers.
A study found that long-term vitamin E supplementation had no clear impact on fatal and nonfatal cancers, major cardiovascular events, or deaths. However, the daily administration of natural source vitamin E increased the risk of heart failure.
A recent study found that Medicaid patients diagnosed with late-stage cancer have significantly poorer survival rates than those diagnosed earlier. The median survival was 18 months for late enrollers compared to 38 months for early enrollers and non-Medicaid patients.
A study found that most patients would be interested in learning aggregate results of trials they participated in, regardless of future care impact. Participants who received results by mail were generally comfortable with this method, and 90% were glad to have been offered the results.
A new chemotherapy combination has shown significant improvement in survival rates for brain tumour patients, with almost half of those with an inactivated MGMT gene surviving after 2 years. The treatment also did not negatively impact patients' quality of life, offering a promising breakthrough in glioblastoma treatment.
Researchers have found that a combination of surgery and intraperitoneal hyperthermic chemotherapy (IPHC) improves overall survival and quality of life in patients with tumors of the appendix, small bowel, ovarian cancer, colon, rectum, stomach, and mesothelioma. The treatment has been shown to be effective for high-grade and low-grade...
A study by American College of Radiology found MRI to be useful in assessing suspected breast cancer patients, detecting additional cancers not visible on mammography or sonography. The use of computer-assisted diagnosis improved accuracy and led to recommended mastectomies for some patients.
A pilot study found cryoablation to be an effective treatment for cancer patients' severe pain, providing relief until the end of life. The procedure involves freezing tumor tissue and surrounding areas to kill cancer cells and ease pain, with most patients tolerating it well despite some nerve damage in one patient.
Researchers have identified a novel marker, AP-2y, for detecting testicular cancer in semen samples. The test showed a sensitivity of 46% and was highly specific, with no false-positives.
A new study reveals that referrals to palliative care come too late to improve quality of life for cancer patients. Researchers surveyed 318 family members and found that only 48% thought referral timing was appropriate, while most believed care was given too late.
A study published in the Journal of the National Cancer Institute found that increases in managed care market share were not associated with improved quality of care for cancer patients, except for a specific blood test. The authors conclude that expansion of managed care may not improve quality of care for all patients.
A new test, NMP22 tumor marker assay, has been shown to be three times more effective than a traditional laboratory test in detecting bladder cancer. The test can detect the disease in patients with blood in their urine and certain risk factors, such as smoking and exposure to chemicals.
A new, point-of-care urine-based test for the protein NMP22 proteomic marker shows promise in detecting bladder cancer, particularly in patients at elevated risk. The test identified several malignancies missed by initial cystoscopy and detected muscle invasive cancers with high sensitivity.
A UCLA study found that green tea extract may help fight bladder cancer by interrupting the development of invasive cells. The extract affects actin remodeling, a process crucial for cell movement and invasion.
A new leukemia drug treatment has shown promise for MDS patients with 5q minus syndrome, becoming transfusion independent in 91% of cases. The defective chromosome abnormality may be linked to other serious cancers, including leukemias and small cell lung cancer.
Patients with cancer have a significantly increased risk of developing venous thrombosis, with the risk highest in the first few months after diagnosis. The study found that patients with hematological, lung, or gastrointestinal cancers had a higher risk compared to those without cancer.
A third of European cancer patients use CAM, with women, younger patients, and those with poor prognosis using it more often. The most commonly used CAM therapies were herbs, homeopathy, and spiritual therapies.
A large study of Swedish twins found no association between neuroticism, extraversion, and increased cancer risk. Despite previous hypotheses linking these traits to cancer, the research suggests that certain personality traits do not influence cancer risk.
The study identified specific characteristics of tissues removed during surgery as risk factors for endometrial cancer recurrence. Approximately one-third of patients with endometrial cancer in the US may benefit from enrollment in clinical trials addressing new treatment approaches.
A study of 90 patients reveals 50% experienced delirium, with distinct clusters of symptoms including psychotic problems, cognitive impairment, and mood disturbance. Early recognition is crucial to prevent poor outcomes, as delirium can lead to increased risk of falls, infections, and mortality.
Fewer than half of patients had received at least one screening test more than six months prior to diagnosis. Patients with a history of screening had earlier stage and presumably more treatable disease, highlighting the underuse of colorectal procedures in clinical practice.
Researchers found that 39% of healthy patients with mesenteric lymph nodes had no evidence of disease one year after their initial examination. Follow-up imaging is not necessary for patients with multiple small nodes scattered throughout the abdomen.
Scientists have discovered a new gene, Bnip3L, that helps p53 eliminate cancer cells under low-oxygen conditions. Silencing this gene allows tumors to grow more aggressively in hypoxic environments.
Researchers analyzed data from Iceland's National Cancer Registry and deCODE genetics database to investigate cancer risk in families. The study found that for 16 out of 27 cancers studied, relatives of patients were at a significantly higher risk of developing the same type of cancer. Lifestyle factors like smoking and diet also contr...